The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 23, 2019
Filed:
Feb. 14, 2018
Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Applicant:
Heron Therapeutics, Inc., Redwood City, CA (US);
Inventors:
Steven Y. Ng, San Francisco, CA (US);
Hui-Rong Shen, Fremont, CA (US);
Jorge Heller, Ashland, OR (US);
Assignee:
Heron Therapeutics, Inc., Redwood City, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/439 (2006.01); A61K 31/435 (2006.01); A61K 31/46 (2006.01); A61K 31/416 (2006.01); A61K 47/30 (2006.01); A61P 1/08 (2006.01); C07D 319/04 (2006.01); A61K 47/34 (2017.01); A61K 8/85 (2006.01); A61K 8/86 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/16 (2006.01); A61K 31/765 (2006.01); A61K 47/10 (2017.01); A61Q 19/00 (2006.01); A61K 31/445 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61Q 15/00 (2006.01); A61Q 17/04 (2006.01);
U.S. Cl.
CPC ...
A61K 47/34 (2013.01); A61K 8/85 (2013.01); A61K 8/86 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 9/06 (2013.01); A61K 9/1647 (2013.01); A61K 31/439 (2013.01); A61K 31/445 (2013.01); A61K 31/573 (2013.01); A61K 31/765 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61Q 19/00 (2013.01); A61Q 15/00 (2013.01); A61Q 17/04 (2013.01);
Abstract
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.